Preliminary activity and safety results from a phase I clinical trial of PF-00299804, an irreversible pan-HER inhibitor, in patients (pts) with NSCLC

No abstract is available for this paper.

• Publication year

  2008

• Venue

  Journal of Clinical Oncology

• Publication date

  2008-05-20

• Fields of study

  Medicine

• Identifiers
  DOI 10.1200/JCO.2008.26.15_SUPPL.8027
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• No references are available for this paper.

• Design, synthesis and biological evaluation of cinnamamide-quinazoline derivatives as potential EGFR inhibitors to reverse T790M mutation.

  2021cites this paper
• Synthesis and evaluation of azalamellarin N and its A-ring-modified analogues as non-covalent inhibitors of the EGFR T790M/L858R mutant.

  2021cites this paper
• Title Hepatocyte growth factor reduces susceptibility to an irreversible epidermalgrowth factor receptor inhibitor in EGFR-T 790 M mutant lung cancer

  2017cites this paper
• The marine‐derived pachycladin diterpenoids as novel inhibitors of wild‐type and mutant EGFR

  2017cites this paper
• Discovery of a Noncovalent, Mutant-Selective Epidermal Growth Factor Receptor Inhibitor.

  2016cites this paper
• Structure-Based Virtual Screening for Defeating Drug Resistant Form of EGFR Protein.

  2016cites this paper
• Novel 4-anilinoquinazoline derivatives featuring an 1-adamantyl moiety as potent EGFR inhibitors with enhanced activity against NSCLC cell lines.

  2016cites this paper
• Tyrosine Kinase Inhibitors. 20. Optimization of Substituted Quinazoline and Pyrido[3,4-d]pyrimidine Derivatives as Orally Active, Irreversible Inhibitors of the Epidermal Growth Factor Receptor Family.

  2016cites this paper
• Short report Open Access

  2015cites this paper
• Noncovalent Mutant Selective Epidermal Growth Factor Receptor Inhibitors: A Lead Optimization Case Study.

  2015cites this paper
• Fighting cancer drug resistance: Opportunities and challenges for mutation-specific EGFR inhibitors.

  2015cites this paper
• Second generation tyrosine kinase inhibitors for the treatment of metastatic non-small-cell lung cancer

  2014cites this paper
• Small-molecule EGFR tyrosine kinase inhibitors for the treatment of cancer

  2014cites this paper
• EGFR-Targeted Therapies in Non-small Cell Lung Cancer

  2014cites this paper
• Guide to Targeted Therapies: EGFR Mutations in NSCLC

  2014cites this paper
• Discovery of Selective and Noncovalent Diaminopyrimidine-Based Inhibitors of Epidermal Growth Factor Receptor Containing the T790M Resistance Mutation

  2014cites this paper
• Driver oncogene mutations and personalized treatment of lung cancer

  2013cites this paper
• An update on molecularly targeted therapies in second- and third-line treatment in non-small cell lung cancer: focus on EGFR inhibitors and anti-angiogenic agents

  2013cites this paper
• Irreversible EGFR-TKIs: dreaming perfection.

  2013cites this paper
• A phase I, open-label, mass balance study of [14C] dacomitinib (PF-00299804) in healthy male volunteers

  2013cites this paper
• Dacomitinib, a new therapy for the treatment of non-small cell lung cancer

  2013cites this paper
• Noncovalent wild-type-sparing inhibitors of EGFR T790M.

  2013cites this paper
• Development of personalized treatments in lung cancer: focusing on the EGFR mutations and beyond

  2013cites this paper
• Second-generation epidermal growth factor receptor tyrosine kinase inhibitors in lung cancers.

  2013cites this paper
• Signaling and Feedback Networks Underlying Senstivity and Resistance to Kinase Inhibitors in Oncogene Addicted Cancers

  2013cites this paper
• Emerging New Agents for the Management of Patients with Non-Small Cell Lung Cancer

  2012cites this paper
• Overcoming molecular mechanisms of resistance to first-generation epidermal growth factor receptor tyrosine kinase inhibitors.

  2012cites this paper
• Mechanisms of Resistance to Epidermal Growth Factor Receptor Inhibitors and Novel Therapeutic Strategies to Overcome Resistance in NSCLC Patients

  2012cites this paper
• The effect of dacomitinib (PF-00299804) on CYP2D6 activity in healthy volunteers who are extensive or intermediate metabolizers

  2012cites this paper
• Second-generation irreversible epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs): a better mousetrap? A review of the clinical evidence.

  2012cites this paper
• Individualized therapy for patients with non-small cell lung cancer: emerging trends and challenges.

  2012cites this paper
• Hsp90 Inhibition Overcomes HGF-Triggering Resistance to EGFR-TKIs in EGFR-Mutant Lung Cancer by Decreasing Client Protein Expression and Angiogenesis

  2012cites this paper
• Irreversible EGFR inhibitors in advanced non-small-cell lung carcinoma: rationale and clinical evidence

  2012cites this paper
• Genotype-driven therapies for non-small cell lung cancer: focus on EGFR, KRAS and ALK gene abnormalities

  2011cites this paper
• Hepatocyte Growth Factor Expression in EGFR Mutant Lung Cancer with Intrinsic and Acquired Resistance to Tyrosine Kinase Inhibitors in a Japanese Cohort

  2011cites this paper
• Hepatocyte Growth Factor Expression in EGFR Mutant Lung Cancer with Intrinsic and Acquired Resistance to Tyrosine Kinase Inhibitors in a Japanese Cohort

  2011cites this paper
• The role of irreversible HER family inhibition in the treatment of patients with non-small cell lung cancer.

  2011cites this paper
• Dissecting therapeutic resistance to RAF inhibition in melanoma by tumor genomic profiling.

  2011cites this paper
• Non-small-cell lung cancer.

  2011cites this paper
• New molecular targeted therapies for advanced non-small-cell lung cancer.

  2011cites this paper
• Resistance to Targeted Therapies As a Result of Mutation(s) in the Target

  2011cites this paper
• Preexistence and clonal selection of MET amplification in EGFR mutant NSCLC.

  2010cites this paper
• Hepatocyte Growth Factor Reduces Susceptibility to an Irreversible Epidermal Growth Factor Receptor Inhibitor in EGFR-T790M Mutant Lung Cancer

  2010cites this paper
• New strategies to overcome limitations of reversible EGFR tyrosine kinase inhibitor therapy in non-small cell lung cancer.

  2010cites this paper
• 表皮生长因子/HER2抑制剂在非小细胞肺癌患者治疗中的作用综述

  2010cites this paper
• Rational, biologically based treatment of EGFR-mutant non-small-cell lung cancer

  2010cites this paper
• Randomized Phase II Multicenter Trial of Two Schedules of Lapatinib as First- or Second-Line Monotherapy in Patients with Advanced or Metastatic Non–Small Cell Lung Cancer

  2010cites this paper
• Somatic Genetic Alterations and Implications for Targeted Therapies in Cancer (GIST, CML, Lung Cancer)

  2010cites this paper
• Personalizing therapy in an epidermal growth factor receptor-tyrosine kinase inhibitor-resistant non-small-cell lung cancer using PF-00299804 and trastuzumab.

  2010cites this paper
• A review of epidermal growth factor receptor/HER2 inhibitors in the treatment of patients with non-small-cell lung cancer.

  2010cites this paper
• Targeting epidermal growth factor receptor in the treatment of non-small-cell lung cancer

  2010cites this paper
• Advances in target therapy for lung cancer.

  2010cites this paper
• The Role of Irreversible EGFR Inhibitors in the Treatment of Non-Small Cell Lung Cancer: Overcoming Resistance to Reversible EGFR Inhibitors

  2010influential citation
• Amplification of EGFR T790M causes resistance to an irreversible EGFR inhibitor

  2010influential citation
• The role of irreversible EGFR inhibitors in the treatment of non-small cell lung cancer: overcoming resistance to reversible EGFR inhibitors.

  2010influential citation
• Epidermal growth factor receptor tyrosine kinase inhibitors in elderly or poor performance status patients with advanced non-small cell lung cancer

  2009cites this paper
• New targeted therapies for non-small-cell lung cancer

  2009cites this paper
• Acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancers dependent on the epidermal growth factor receptor pathway.

  2009cites this paper
• Small-molecule inhibitors of the human epidermal receptor family

  2009cites this paper
• Targeted therapies in the treatment of advanced/metastatic NSCLC.

  2009cites this paper
• Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Non–Small Cell Lung Cancer

  2009cites this paper
• Recent advances of novel targeted therapy in non-small cell lung cancer

  2009cites this paper
• Clinical Medicine of Molecular Targeted Drugs -New Molecular Targeted Drugs for Lung Cancer-

  2009cites this paper
• Second-generation epidermal growth factor tyrosine kinase inhibitors in non-small cell lung cancer

  2009cites this paper
• 1．開発段階の分子標的薬 1）VEGFR-TKIとEGFR-TKI

  2009cites this paper
• Hepatocyte Growth Factor Reduces Susceptibility to an Irreversible Epidermal Growth Factor Receptor Inhibitor in EGFR-T790M Mutant Lung Cancer

  2009cites this paper
• The role of EGFR inhibition in the treatment of non-small cell lung cancer.

  2009cites this paper
• Novel mutant-selective EGFR kinase inhibitors against EGFR T790M

  2009cites this paper
• Erlotinib: applications in therapy and current status of research

  2009cites this paper
• Non-small cell lung cancer

  2008cites this paper
• Targeted therapy for the treatment of non-small cell lung cancer: focus on inhibition of epidermal growth factor receptor.

  2008cites this paper
• Novel therapies in breast cancer: what is new from ASCO 2008

  2008cites this paper
• Inhibiteurs de la transduction du signal : quoi de neuf à l'ASCO 2008?

  2008cites this paper
• Cancer Management and Research Dovepress Role of Erlotinib in First-line and Maintenance Treatment of Advanced Non-small-cell Lung Cancer

  year unknowncites this paper